StreetInsider.com News Articles

NEC contributes to AI powered Vaccine Design through the EU funded PREPAIR VAC Pandemic Preparedness Project

Tue, 27 Oct 2026 06:00:00 -0400

Tokyo, Japan and Schiphol, Netherlands, Oct 27, 2026 - (JCN Newswire) - - NEC Corporation (NEC; TSE: 6701) today announced its participation in PREPAIR VAC, a Horizon Europe-funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design. The grant has been awarded to NEC OncoImmunity AS (NOI)-a wholly owned subsidiary of NEC Bio within NEC Corporation-alongside several European partners comprising a research consortium.

This four-year research grant beginning in September 2026, with a total budget of approximately E6.5M, aims to address major challenges in vaccine design in the context of pandemic preparedness,

NEC Develops AI Technology Using VLM to Detect Early Signs of Disasters from Live Camera Footage

Fri, 23 Oct 2026 11:18:00 -0400

TOKYO, Oct 24, 2026 - (JCN Newswire) - - NEC Corporation (NEC; TSE: 6701) has developed an AI technology that uses a vision-language model (VLM) to assign numerical values (scores) for on-site conditions from live camera footage monitoring roads and rivers, enabling the early detection of precursors to disasters such as river flooding, inundation, and snow accumulation. This technology can utilize existing live cameras operated by local governments, government agencies, and infrastructure operators, making it easy to deploy at disaster monitoring sites while streamlining monitoring operations and accelerating response decisions. NEC aims to put this technology into practical use

NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026

Fri, 23 Oct 2026 10:35:00 -0400

TOKYO, Japan, Oct 23, 2026 - (JCN Newswire) - - NEC Bio will be presenting results from the Phase I/II TNBC clinical trial of its orally administered individualized neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). The findings are being presented in an e-poster at the ESMO Congress in Madrid, Spain, from October 23 to 27, 2026.

NECVAX-NEO1 is an AI powered individualized bacteria-based oral DNA therapy that combines IMMUNASIGHT(r), NEC Bio's proprietary AI based neoantigen prediction platform for identifying the most immunogenic patient-specific neoepitopes, with TORAPRIME(R), its proprietary

NEC Develops VLM Technologies That Accurately Identify Small-Scale Damage in Disaster Site Images and Adapt to New Types of Damage

Fri, 16 Oct 2026 08:52:00 -0400

TOKYO, Oct 16, 2026 - (JCN Newswire) - - NEC Corporation (NEC; TSE: 6701) has developed two new technologies for Vision-Language Models (VLMs), VLM-based Local Region Understanding (*1) and Continual Learning for VLMs (*2), which are expected to be utilized in rescue operations and recovery efforts by local governments and other organizations. VLM-based Local Region Understanding accurately identifies small-scale damage visible within images collected from disaster sites. Continual Learning for VLMs enables new types of damage information to be added as search criteria while maintaining the VLM's original recognition capabilities. These technologies are the result of joint research with

NEC exhibits at the 32nd ITS World Congress, a conference and exhibition focused on mobility

Fri, 16 Oct 2026 08:01:00 -0400

TOKYO, Oct 16, 2026 - (JCN Newswire) - - NEC Corporation (NEC; TSE: 6701) has announced its participation in the upcoming 32nd ITS World Congress as an exhibitor at the ITS Japan Pavilion, which will showcase public- and private-sector exhibitors affiliated with ITS Japan. Additionally, NEC will present a technical paper during a session at the event. This five-day conference and exhibition, which brings together experts from industry, government, and academia, focuses on intelligent transport systems (ITS) and will be held in Gangneung, Korea, from October 19 (Monday) to October 23 (Friday), 2026 (ITS Japan Pavilion; Booth number: S25).

The

Next-Generation Cancer Immunotherapy Using Quantum Computing Selected for NEDO Demonstration Program

Thu, 08 Oct 2026 07:33:00 -0400

TOKYO, Oct 8, 2026 - (JCN Newswire) - - A joint research and development project titled "Development and Demonstration of a Computational and Evaluation Platform for Next-Generation Cancer Immunotherapy Using Quantum Computing Technology," undertaken by NEC Corporation (NEC), Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical), the Japanese Foundation for Cancer Research (JFCR), the National Institute of Advanced Industrial Science and Technology (AIST), and Waseda University, has been selected for the Large-Scale Demonstration for Use Case Creation under the Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems administered by Japan's New Energy and Industrial Technology

NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2026"

Tue, 15 Sep 2026 07:37:00 -0400

TOKYO, Sept 15, 2026 - (JCN Newswire) - - NEC Corporation (NEC; TSE: 6701) has published the "ESG Databook 2026," a report on its Environmental, Social, and Governance (ESG) initiatives from April 2025 onwards.

NEC ESG Databook 2026

URL: https://www.nec.com/en/global/sustainability/report/index.html

In its Mid-Term Management Plan 2030 (*) announced in May 2026, NEC redefined the company's social role and unveiled its "Vision for Creating Social Value" titled "Empower Humanity-Delivering innovation and peace of mind." To realize this vision, NEC is reviewing the themes (materiality) that should be prioritized from a sustainability perspective and striving to maximize corporate value through the implementation

Bernstein SocGen Group Starts NEC Corporation (6701:JP) (NIPNF) at Outperform

Tue, 15 Sep 2026 05:17:16 -0400

Bernstein SocGen Group analyst Kengo Makita initiates coverage on NEC Corporation (6701:JP) (OTC: NIPNF) with a Outperform rating and a price target of JPY5,800.00.

Bernstein SocGen Group Starts NEC Corporation (6701:JP) (NIPNF) at Outperform

Tue, 15 Sep 2026 05:17:16 -0400

Bernstein SocGen Group analyst Kengo Makita initiates coverage on NEC Corporation (6701:JP) (OTC: NIPNF) with a Outperform rating and a price target of JPY5,800.00.

Bernstein SocGen Group Starts NEC Corporation (6701:JP) (NIPNF) at Outperform

Tue, 15 Sep 2026 05:17:16 -0400

Bernstein SocGen Group analyst Kengo Makita initiates coverage on NEC Corporation (6701:JP) (OTC: NIPNF) with a Outperform rating and a price target of JPY5,800.00.

Bernstein SocGen Group Starts NEC Corporation (6701:JP) (NIPNF) at Outperform

Tue, 15 Sep 2026 05:17:16 -0400

Bernstein SocGen Group analyst Kengo Makita initiates coverage on NEC Corporation (6701:JP) (OTC: NIPNF) with a Outperform rating and a price target of JPY5,800.00.

NEC Orchestrating Future Fund Invests in U.S.-based Dexmate, Provider of Humanoid Robot "VEGA" and Physical AI Platform

Thu, 27 Aug 2026 08:01:00 -0400

TOKYO, Japan, Aug 27, 2026 - (JCN Newswire) - - NEC Corporation's (NEC; TSE: 6701) ecosystem-based corporate venture capital (CVC) fund, NEC Orchestrating Future Fund (NOFF) (*1), has invested in Dexmate, Inc. (Dexmate), a U.S. startup providing the AI-controlled humanoid robot "VEGA" and a Physical AI development platform.

In recent years, advances in generative AI have raised expectations not only for the enhancement of operations and services in the digital realm, but also for "Physical AI," AI capable of safely interacting with people and environments in the real world. However, in the development and operation of robots, one of the

NEC Orchestrating Future Fund Invests in U.S.-based Dexmate, Provider of Humanoid Robot "VEGA" and Physical AI Platform

Thu, 27 Aug 2026 08:01:00 -0400

NEC Orchestrating Future Fund Invests in U.S.-based Dexmate, Provider of Humanoid Robot "VEGA" and Physical AI Platform

Thu, 27 Aug 2026 08:01:00 -0400

NEC Orchestrating Future Fund Invests in U.S.-based Dexmate, Provider of Humanoid Robot "VEGA" and Physical AI Platform

Thu, 27 Aug 2026 08:01:00 -0400

NEC Corporation (6701:JP) (NIPNF) PT Raised to JPY6,300 at Citi

Wed, 26 Aug 2026 04:26:28 -0400

Citi analyst Masahiro Shibano raised the price target on NEC Corporation (6701:JP) (OTC: NIPNF) to JPY6,300.00 (from JPY5,100.00) while maintaining a Buy rating.

NEC Corporation (6701:JP) (NIPNF) PT Raised to JPY6,300 at Citi

Wed, 26 Aug 2026 04:26:28 -0400

Citi analyst Masahiro Shibano raised the price target on NEC Corporation (6701:JP) (OTC: NIPNF) to JPY6,300.00 (from JPY5,100.00) while maintaining a Buy rating.

NEC Corporation (6701:JP) (NIPNF) PT Raised to JPY6,300 at Citi

Wed, 26 Aug 2026 04:26:28 -0400

Citi analyst Masahiro Shibano raised the price target on NEC Corporation (6701:JP) (OTC: NIPNF) to JPY6,300.00 (from JPY5,100.00) while maintaining a Buy rating.

NEC Corporation (6701:JP) (NIPNF) PT Raised to JPY6,300 at Citi

Wed, 26 Aug 2026 04:26:28 -0400

Citi analyst Masahiro Shibano raised the price target on NEC Corporation (6701:JP) (OTC: NIPNF) to JPY6,300.00 (from JPY5,100.00) while maintaining a Buy rating.

ITU-T Standardizes Framework of Low-Latency and Energy-Efficient Networks to Support the AI Era